Reviews
Interstitial lung disease in patients with systemic sclerosis: what can we learn from the SENSCIS trial?
S. Assassi1, S. Tumuluri2, R.W. Levin3
- Division of Rheumatology, University of Texas McGovern Medical School, Houston, TX, USA. shervin.assassi@uth.tmc.edu
- Pacific Coast Dermatology and Wellness Center, Redwood City, CA, USA.
- University of South Florida, Tampa, FL, USA.
CER17003
2023 Vol.41, N°8
PI 1713, PF 1719
Reviews
Free to view
(click on article PDF icon to read the article)
PMID: 37534955 [PubMed]
Received: 19/07/2023
Accepted : 26/07/2023
In Press: 03/08/2023
Published: 03/08/2023
Abstract
The SENSCIS trial of nintedanib versus placebo is the largest trial conducted to date in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD). This trial enrolled 576 patients with an extent of fibrotic ILD on high-resolution computed tomography of >10%. Median time since first non-Raynaud symptom was 3.4 years. Almost half of the patients were receiving a stable dose of mycophenolate at baseline. Key findings of the trial included that at baseline, despite having significant lung fibrosis on HRCT and impairment in lung function, 20% of the patients did not have cough and 30% did not have dyspnoea. Over 52 weeks, a marked decline in forced vital capacity (FVC) was observed (-112.0 mL/year in patients with diffuse cutaneous SSc [dcSSc] and -74.5 mL/year in patients with limited cutaneous SSc [lcSSc] in the placebo group). Loss of FVC was associated with an increased risk of SSc-related hospitalisation or death. Although certain subgroups of patients were at higher risk of progression, it was not possible to make a robust prediction of FVC decline based on baseline characteristics. The relative effect of nintedanib versus placebo on reducing the rate of FVC decline was consistent across subgroups based on factors including anti-topoisomerase I antibody (ATA) status, dcSSc vs. lcSSc, and use of mycophenolate at baseline. The side-effects of nintedanib were mainly gastrointestinal events, particularly diarrhoea. Nintedanib did not have a significant effect on skin fibrosis or health-related quality of life. Overall, the results of the SENSCIS trial support the importance of prompt identification and treatment of SSc-ILD and the consideration of nintedanib as a treatment option.
